Author:
Pitcovski Jacob,Gruzdev Nady,Abzach Anna,Katz Chen,Ben-Adiva Ran,Schwartz Michal Brand,Yadid Itamar,Haviv Hadar,Rapoport Irena,Bloch Itai,Shadmon Roy,Eitan Zohar,Eliahu Dalia,Hilel Talia,Laster Morris,Tal Sigal Kremer,Tennenbaum Tamara Byk,Shahar Ehud
Abstract
AbstractThe rapid spread of the COVID-19 pandemic, with its devastating medical and economic impacts, triggered an unprecedented race toward development of effective vaccines. The commercialized vaccines are parenterally administered, which poses logistic challenges, while adequate protection at the mucosal sites of virus entry is questionable. Furthermore, essentially all vaccine candidates target the viral spike (S) protein, a surface protein that undergoes significant antigenic drift. This work aimed to develop an oral multi-antigen SARS-CoV-2 vaccine comprised of the receptor binding domain (RBD) of the viral S protein, two domains of the viral nucleocapsid protein (N), and heat-labile enterotoxin B (LTB), a potent mucosal adjuvant. The humoral, mucosal and cell-mediated immune responses of both a three-dose vaccination schedule and a heterologous subcutaneous prime and oral booster regimen were assessed in mice and rats, respectively. Mice receiving the oral vaccine compared to control mice showed significantly enhanced post-dose-3 virus-neutralizing antibody, anti-S IgG and IgA production and N-protein-stimulated IFN-γ and IL-2 secretion by T cells. When administered as a booster to rats following parenteral priming with the viral S1 protein, the oral vaccine elicited markedly higher neutralizing antibody titres than did oral placebo booster. A single oral booster following two subcutaneous priming doses elicited serum IgG and mucosal IgA levels similar to those raised by three subcutaneous doses. In conclusion, the oral LTB-adjuvanted multi-epitope SARS-CoV-2 vaccine triggered versatile humoral, cellular and mucosal immune responses, which are likely to provide protection, while also minimizing technical hurdles presently limiting global vaccination, whether by priming or booster programs.HighlightsMigVax-101 is a multi-epitope oral vaccine for SARS-CoV-2.MigVax-101 elicits neutralizing IgG and IgA production and cellular responses in miceMigVax-101 serves as an effective booster in rats to a parenteral anti-S1 vaccine.
Publisher
Cold Spring Harbor Laboratory
Reference50 articles.
1. WHO Coronavirus disease (COVID-19) situation report https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-11-may-2021.
2. WHO Draft landscape and tracker of COVID-19 candidate vaccines Published: 14 May 2021 https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
3. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies;Protein Cell,2015
4. Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate;Microb Cell Fact,2018
5. Cross-protective immunity of the haemagglutinin stalk domain presented on the surface of Lactococcus lactis against divergent influenza viruses in mice;Virulence,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献